Clinical commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Document first published:: 6 November 2023
Page updated:: 6 November 2023
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Trametinib is recommended to be available off-label as a routine commissioning treatment option for adults with recurrent or progressive low grade serous ovarian cancer within the criteria set out in this document.

Document

Commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

PDF
158 KB
7 pages

Document

Clinical panel report: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Clinical panel report: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

PDF
92 KB
3 pages

Document

Clinical priorities advisory group report: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Clinical priorities advisory group report: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

PDF
167 KB
9 pages

Document

Equality and Health Inequalities Impact Assessment (EHIA): Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Equality and Health Inequalities Impact Assessment (EHIA): Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

PDF
112 KB
11 pages

Document

Evidence review: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Evidence review: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

PDF
423 KB
38 pages